Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristy L S Miskimen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Protocols|July 3, 2023
Isolation of Genomic DNA from Mammalian Cells and Fixed TissueKristy L S Miskimen, Penelope L Miron
Current Protocols in Human Genetics|January 12, 2017
Assay for Transposase-Accessible Chromatin Using Sequencing (ATAC-seq) Data AnalysisKristy L S Miskimen, E Ricky Chan, Jonathan L Haines
Oncotarget|May 17, 2013
FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapiesRocky Cipriano, Kristy L S Miskimen, Benjamin L Bryson, et al.
Breast Cancer Research and Treatment|March 10, 2015
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancerCallie R Merry, Sarah McMahon, Cheryl L Thompson, et al.
Molecular Cancer Research : MCR|April 17, 2014
Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancerRocky Cipriano, Kristy L S Miskimen, Benjamin L Bryson, et al.
The Journal of Clinical Investigation|August 14, 2012
FAM83B mediates EGFR- and RAS-driven oncogenic transformationRocky Cipriano, James Graham, Kristy L S Miskimen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Protocols|July 3, 2023
Isolation of Genomic DNA from Mammalian Cells and Fixed TissueKristy L S Miskimen, Penelope L Miron
Current Protocols in Human Genetics|January 12, 2017
Assay for Transposase-Accessible Chromatin Using Sequencing (ATAC-seq) Data AnalysisKristy L S Miskimen, E Ricky Chan, Jonathan L Haines
Oncotarget|May 17, 2013
FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapiesRocky Cipriano, Kristy L S Miskimen, Benjamin L Bryson, et al.
Breast Cancer Research and Treatment|March 10, 2015
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancerCallie R Merry, Sarah McMahon, Cheryl L Thompson, et al.
Molecular Cancer Research : MCR|April 17, 2014
Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancerRocky Cipriano, Kristy L S Miskimen, Benjamin L Bryson, et al.
The Journal of Clinical Investigation|August 14, 2012
FAM83B mediates EGFR- and RAS-driven oncogenic transformationRocky Cipriano, James Graham, Kristy L S Miskimen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Pageof 1